公开(公告)号：US20240327388A1

公开(公告)日：2024-10-03

申请号：US18564512

申请日：2022-05-27

申请人： JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. ,  SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.

发明人： Fanglong YANG ,  Minqiang JIA ,  Huanyu TANG ,  Yonglei QUE ,  Feng HE ,  Weikang TAO

IPC分类号： C07D405/12 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/706 ,  A61P37/06 ,  C07D215/38 ,  C07D401/12 ,  C07D405/14 ,  C07D413/12 ,  C07D491/056 ,  C07H1/00 ,  C07H17/04

CPC分类号： C07D405/12 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/706 ,  A61P37/06 ,  C07D215/38 ,  C07D401/12 ,  C07D405/14 ,  C07D413/12 ,  C07D491/056 ,  C07H1/00 ,  C07H17/04

摘要： The present invention relates to a quinolinamine compound, a preparation method therefor and an application thereof in pharmaceuticals. Specifically, the present invention relates to a quinolinamine compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a therapeutic agent, especially use thereof as a miRNA regulator and use thereof in preparation of a drug for treating diseases or conditions that can be improved by regulating miRNA levels.

公开(公告)号：US12071412B2

公开(公告)日：2024-08-27

申请号：US18104691

申请日：2023-02-01

申请人： NOBO Medicine Inc.

发明人： Alfred P. Spada ,  Robert J. Temansky ,  Michael Mueller

IPC分类号： C07D239/42 ,  A61P29/00 ,  C07C233/56 ,  C07D213/75 ,  C07D215/38 ,  C07D215/40 ,  C07D217/24 ,  C07D239/34 ,  C07D257/04

CPC分类号： C07D239/42 ,  A61P29/00 ,  C07C233/56 ,  C07D213/75 ,  C07D215/38 ,  C07D215/40 ,  C07D217/24 ,  C07D239/34 ,  C07D257/04

摘要： Provided herein are compounds of formula I, compositions comprising the compounds and method of treating various diseases with the compounds and compositions.

公开(公告)号：US20240092760A1

公开(公告)日：2024-03-21

申请号：US18334325

申请日：2023-06-13

申请人： IMMUNESENSOR THERAPEUTICS, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Jian QIU ,  Qi WEI ,  Matt TSCHANTZ ,  Heping SHI ,  Youtong WU ,  Huiling TAN ,  Lijun SUN ,  Chuo CHEN ,  Zhijian CHEN

IPC分类号： C07D401/14 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07F9/6503 ,  C07F9/6506

CPC分类号： C07D401/14 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07F9/65031 ,  C07F9/6506

摘要： The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

公开(公告)号：US11649258B2

公开(公告)日：2023-05-16

申请号：US17173500

申请日：2021-02-11

申请人： Johnson Matthey Public Limited Company

发明人： Thomas Colacot ,  Ruishan Chow ,  Andrew Jon DeAngelis

IPC分类号： C07F15/00 ,  C07D215/38 ,  C07B37/04 ,  C07B43/04 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07D295/096 ,  C07D213/127 ,  C07D213/24 ,  C07D213/50 ,  C07D213/56 ,  C07D307/46 ,  C07C45/68 ,  C07C17/32

CPC分类号： C07F15/006 ,  C07B37/04 ,  C07B43/04 ,  C07C17/32 ,  C07C45/68 ,  C07D213/127 ,  C07D213/24 ,  C07D213/50 ,  C07D213/56 ,  C07D215/38 ,  C07D295/096 ,  C07D307/46 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07C45/68 ,  C07C49/84 ,  C07C17/32 ,  C07C22/08

摘要： The present invention provides a palladium(II) complex of formula (1).




R12, m, and X are described in the specification.
The invention also provides a process for the preparation of the complex, and its use in carbon-carbon and carbon-heteroatom coupling reactions.

公开(公告)号：US11649210B2

公开(公告)日：2023-05-16

申请号：US16994954

申请日：2020-08-17

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier Scherrer ,  Jamal Tazi ,  Florence Mahuteau ,  Romain Najman

IPC分类号： C07D215/38 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C12Q1/6883 ,  G01N33/50 ,  C07D401/12

CPC分类号： C07D215/38 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C07D401/12 ,  C12Q1/6883 ,  G01N33/5023 ,  G01N33/5055 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178

摘要： The present disclosure relates to the use of a compound of formula (I)




or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein:





means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(═O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:

公开(公告)号：US20230131025A1

公开(公告)日：2023-04-27

申请号：US17799234

申请日：2021-02-08

申请人： Betta Pharmaceuticals Co., Ltd.

发明人： Xiangyong LIU ,  Changyong QIU ,  Mengqiang LIU ,  Xiaodong SONG ,  Qichao SHEN ,  Guolong DU ,  Haitong SHENG ,  Lieming DING ,  Jiabing WANG

IPC分类号： C07D401/12 ,  C07D215/38 ,  A61P35/00 ,  C07D401/14 ,  C07D417/14

摘要： The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.

公开(公告)号：US20230117592A1

公开(公告)日：2023-04-20

申请号：US17788275

申请日：2020-12-18

申请人： SRI International

发明人： Ling Jong ,  Nathan Collins ,  Raymond Ng

IPC分类号： C07C217/86 ,  C07C217/92 ,  C07D215/38 ,  C07D213/74 ,  C07D249/08 ,  C07D403/12 ,  C07D401/12 ,  C07D409/12 ,  C07D405/06 ,  C07D209/14 ,  C07C211/53 ,  C07D309/04 ,  C07D305/08 ,  C07D295/13 ,  C07C211/54 ,  C07D413/12 ,  C07D405/12 ,  C07C211/56 ,  C07D403/06 ,  C07D405/14

摘要： Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

公开(公告)号：US20220402883A1

公开(公告)日：2022-12-22

申请号：US17805634

申请日：2022-06-06

申请人： Arrakis Therapeutics, Inc.

发明人： Russell C. PETTER ,  James Gregory BARSOUM ,  Gnanasambandam KUMARAVEL ,  Kenneth W. BAIR

IPC分类号： C07D263/24 ,  C07D487/08 ,  C07D413/04 ,  C07H5/06 ,  C07C237/26 ,  C07D215/38 ,  C07D487/04 ,  C07D215/40 ,  A61K31/496

摘要： The present invention provides compounds, compositions thereof, and methods of using the same.

公开(公告)号：US20220396553A1

公开(公告)日：2022-12-15

申请号：US17415382

申请日：2018-12-26

申请人： KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Ae Nim PAE ,  Yun Kyung KIM ,  Sang Min LIM ,  Sungsu LIM ,  Jihye SEONG ,  Jae Wook LEE ,  Ji Yeon SONG ,  Seulgi SHIN ,  Hyean Jeong JEONG ,  Woo Seung SON ,  Haeun LEE ,  Da Mi LIM ,  Seok Kyu KIM ,  Jee Yun AHN ,  Chae Won KIM ,  Ashwini Machhindra LONDHE ,  Lizaveta GOTINA ,  Hyojin KIM ,  Hye Yeon LEE ,  Nam Gyung KIM ,  Eunji CHA ,  Kunhee KIM ,  Ji Woong LIM

IPC分类号： C07D241/42 ,  C07D239/34 ,  C07D239/30 ,  C07D239/26 ,  C07D277/28 ,  C07C255/66 ,  C07D487/04 ,  C07D471/04 ,  C07D231/12 ,  C07D209/14 ,  C07D231/56 ,  C07D215/38 ,  C07D417/12 ,  C07D417/04 ,  C07D277/82 ,  C07D237/14

摘要： The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

公开(公告)号：US20220315535A1

公开(公告)日：2022-10-06

申请号：US17746410

申请日：2022-05-17

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Jamal TAZI

IPC分类号： C07D215/38 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C12Q1/6883 ,  G01N33/50 ,  C07D401/12

摘要： In vitro or ex vivo methods for screening a quinoline derivative, or anyone of its pharmaceutically acceptable salt, presumed effective in treating and/or preventing an inflammatory disease, the method including: providing an eukaryotic cell, bringing into contact said cell with a quinoline derivative, measuring an expression of miR-124 in the cell, and selecting the candidate presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured is increased relatively to a reference value.